Pharmaceuticals, Biotechnology and Life Sciences
Orexigen Therapeutics said that Health Canada has accepted to review a New Drug Submission for marketing approval of its products Contrave (naltrexone HCl and bupropion HCl).
Amgen and Novartis have formed a coalition that will be expanded and, as they hope, bring easier launching of a migraine related product, the USA-based company said late Monday.
Bristol-Myers Squibb and Transgene have entered a new clinical research collaboration to evaluate the safety, tolerability and efficacy of Transgene’s investigational therapeutic vaccine TG4010 in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) + standard chemotherapy (CT) as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) in patients whose tumors have low or undetectable levels of PD-L1.
Novartis’ has posted a first quarter net income down 15% citing a net charge related to the discontinuation of RLX030 ($-0.2 billion), as well as the decline in core operating income.
Bayer has partnered up with Goodbye Malaria to support the objectives of Ending Malaria for Good in Southern Africa.
Eli Lilly’s MONARCH 3 trial has met its primary endpoint of demonstrating statistically significant improvement in progression-free survival (PFS).
STADA Arzneimittel AG has appointed Dr. Ralph Grobecker as Managing Director at STADA GmbH.
Tiziana Life Sciences a cancer drugs making focused clinical stage biotechnology company got approval in Israel to start testing inhibitor of cell cycle dependent kinases (CDKs), milciclib in a phase II clinical trial.
Amryt, the pharmaceutical company focused on treatments for rare and orphan diseases, has enroled first patient into “EASE”, the company’s pivotal Phase 3 clinical trial, which is evaluating AP101 as a potential treatment for the rare, genetic skin disorder, Epidermolysis Bullosa (“EB”).
Europe’s drugmakers pushed for a decision as early as June on the new location for the headquarters of the bloc’s medicines watchdog, which will relocate from London after Britain’s decision to leave the EU.